Track topics on Twitter Track topics that are important to you
The National Cancer Institute's Endocrine Oncology Branch seeks parties to co-develop diagnostic that target altered human miRNA expression such as miRNA-483 and miRNA 100 to accurately predict if a patient's adrenal cortex tumor is benign or malignant.
Adrenocortical carcinomas (ACC) are rare but aggressive cancers and typically have a poor prognosis. Currently, there are limited options for molecular diagnosis to distinguish malignant tumors from benign tumors of this type. As a result there are few treatment strategies for ACC.
This technology describes that altered human miRNA expression such as miRNA-483 and miRNA 100 can accurately predict if a patient''''s adrenal cortex tumor is benign or malignant. Additionally, preliminary results suggest that altering the expression of this miRNA in ACC cells can effect cancer cell growth. Therefore, inhibiting a miRNA may serve as a therapeutic option for ACC.
Pre-clinical (in vivo)
Patterson E, et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy.
Patterson E, et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma.
Original Article: Diagnostics and Therapeutics for Adrenocortical CarcinomasNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
A microRNA (abbreviated miRNA) is a small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals, and some viruses. Key findings: miRNA is involved in the normal functioning of eukaryotic cells, so has dysregulation...